orforglipron
Manufactured by Eli Lilly
First of its kind: Foundayo is the first oral GLP-1 pill specifically FDA-approved for chronic weight management. Unlike Wegovy Pill (semaglutide) and Rybelsus (semaglutide), Foundayo uses a novel small-molecule compound (orforglipron) that can be taken at any time of day without food or water restrictions. Launched April 2026 with a list price of $649/month; LillyDirect self-pay from $149-$349/month depending on dose; Savings Card for commercial insurance as low as $25/month.
Available Brands
Foundayo
First oral GLP-1 pill FDA-approved for chronic weight management. List price $649/mo; LillyDirect self-pay starts at $149/mo; Savings Card $25/mo for eligible commercial insurance.
Overview
FDA Status
FDA Approved
Route
oral
Approved Indications
Dosing
Typical Dose Range
3mg - 36mg daily
Dosing is determined by your prescribing provider based on your individual needs. Most GLP-1 medications follow a gradual titration schedule, starting at a low dose and increasing over several weeks to reduce side effects.
Cost Breakdown
Branded (Retail)
$649/mo
Savings Program
$149/mo
Prices are estimates and may vary by pharmacy, location, and insurance coverage. Contact your provider for accurate pricing.
Common Side Effects
- nausea
- vomiting
- diarrhea
- constipation
- decreased appetite
This is not a complete list of side effects. Talk to your healthcare provider about what to expect and when to seek medical attention.
This site is for educational purposes only and is not medical advice. Always consult a healthcare provider before starting any medication. Full disclaimer
Related Articles
Lilly's Foundayo Sees Modest Launch with Just 1,390 Prescriptions in Debut Week
Eli Lilly's new oral GLP-1 pill Foundayo recorded only 1,390 prescriptions in its first week, a surprisingly modest start that contrasts sharply with Novo's oral Wegovy success.
The DoseFDA Requests Safety Studies for Foundayo Despite Recent Approval
Just days after approving Foundayo, the FDA is asking Eli Lilly for additional data on potential heart, liver, and thyroid cancer risks.
The DoseLilly Responds to FDA Safety Request with Foundayo Heart Trial Data
Eli Lilly released cardiovascular safety data for Foundayo just days after FDA demanded additional studies on potential heart and liver risks.
The DoseFoundayo Hits Pharmacies as FDA Demands Additional Safety Data From Eli Lilly
Eli Lilly's new oral GLP-1 pill Foundayo launched in US pharmacies this week, but the FDA is requiring new safety studies for cardiovascular risks and other concerns.